Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity
Open Access
- 22 December 2023
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 13 (1)
Abstract
Background: T‐cell immunoglobulin and mucin domain‐containing protein 3 (TIM‐3), an immune checkpoint receptor, dampens immune function. TIM‐3 antagonists have entered the clinic.Methods: We analyzed TIM‐3 transcriptomic expression in 514 diverse cancers. Transcript abundance was normalized to internal housekeeping genes and ranked (0–100 percentile) to a reference population (735 tumors; 35 histologies [high≥75 percentile rank]). Ninety tumors (17.5%) demonstrated high TIM‐3 expression.Results: TIM‐3 expression varied between and within tumor types. However, high TIM‐3 expression was more common in pancreatic cancer (20/55 tumors, 36.4%; odds ratio, 95% confidence interval (pancreatic vs. other tumors) = 3.176 (1.733–5.818; p < 0.001, multivariate]). High TIM‐3 also significantly and independently correlated with high PD‐L1 (p = 0.014) and high CTLA‐4 (p < 0.001) transcriptomic expression (multivariate).Conclusions: These observations indicate that TIM‐3 RNA expression is heterogeneous, but more common in pancreatic cancer and in tumors exploiting PD‐L1 and CTLA‐4 checkpoints. Clinical trials with patient selection for matched immune‐targeted combinations may be warranted.Keywords
Funding Information
- National Cancer Institute (P30 CA023100)
This publication has 30 references indexed in Scilit:
- Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory ReceptorsCancer Immunology Research, 2015
- The Expression of Tim-3 in Peripheral Blood of Ovarian CancerDNA and Cell Biology, 2013
- Tim-3 Expression Defines Regulatory T Cells in Human TumorsPLOS ONE, 2013
- Tim-3 Expression in Cervical Cancer Promotes Tumor MetastasisPLOS ONE, 2013
- The T-cell immunoglobulin and mucin domain (Tim) gene family in asthma, allergy, and autoimmunityAllergy and Asthma Proceedings, 2013
- Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicityBlood, 2012
- IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphomaJournal of Clinical Investigation, 2012
- Combining immunotherapy and targeted therapies in cancer treatmentNature Reviews Cancer, 2012
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemiaBlood, 2011
- Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune diseaseNature, 2002